Highlighted publications
Sparidans, R. W., Bosch, T. M., Jörger, M., Schellens, J. H. M., & Beijnen, J. H. (2006). Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. Journal of chromatography. B, 839(1-2), 45-53. [DOI]
Sparidans, R. W., den Hartigh, J., Cremers, S., Beijnen, J. H., & Vermeij, P. (2000). Semi-automated liquid chromatographic analysis of olpadronate in urine and serum using derivatization with (9-fluorenylmethyl)chlorofromate. Journal of chromatography. B, Biomedical sciences and applications, 738, 331-341.
Sparidans, R. W., Claessens, H. A., Van Doremaele, G. H. J., & Van Herk, A. M. (1990). Analysis of poly(styrene-co-methyl acrylate) and poly(styrene-co-butyl acrylate) by high-performance liquid chromatography. Journal of Chromatography A, 508(C), 319-331. [DOI]
Sparidans, R. W., Lagas, J. S., Schinkel, A. H., Schellens, J. H. M., & Beijnen, J. H. (2008). Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma. Journal of chromatography. B, 872(1-2), 77-82. [DOI]
Sparidans, R. W., Rosing, H., Rood, J. J. M., Schellens, J. H. M., & Beijnen, J. H. (2016). Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1033-1034, 390-398. [DOI] [Repository]
Publications
2025
Scholarly publications
Verstegen, R. E. M., Sparidans, R. W., Kostadinova, A. I., Garssen, J., Folkerts, G., Hendriks, R. W., & Willemsen, L. E. M. (2025). Lung Acetate Levels Decline in Correlation With Increased Type 2 Allergic Markers in a House Dust Mite Allergic Mouse Model. Clinical and Translational Allergy, 15(8), Article e70082. [DOI] [Portal]
Ahmed, S., Sparidans, R. W., Vernooij, R. W. M., Mihaila, S. M., Broekhuizen, R., Goldschmeding, R., Nguyen, T. Q., Masereeuw, R., & Gerritsen, K. G. F. (2025). Protein-bound uremic toxin clearance as biomarker of kidney tubular function in diabetic kidney disease. Scientific Reports, 15(1), Article 23406. [DOI] [Portal]
Ahmed, S., Chen, S., Lucas, J. P. F. E., Knoppert, S. N., Harwood, R., Faria, J., Besseling, P. J., Sparidans, R. W., Broekhuizen, R., Westphal, K. G. C., Mihăilă, S. M., Joles, J. A., Goldschmeding, R., Nguyen, T. Q., Wilm, B., Murray, P., Sonnen, A. F.-P., Gerritsen, K. G. F., & Masereeuw, R. (2025). Indoxyl sulfate as a potential tubular function marker across kidney disease models. American Journal of Physiology - Renal Physiology, 329(1), F160-F177. [DOI] [Portal]
2024
Scholarly publications
Rijmers, J., Sparidans, R. W., Acda, M., Loos, N. H. C., Epeslidou, E., Bui, V., Lebre, M. C., Tibben, M., Beijnen, J. H., & Schinkel, A. H. (2024). Brain Exposure to the Macrocyclic ALK Inhibitor Zotizalkib is Restricted by ABCB1, and Its Plasma Disposition is Affected by Mouse Carboxylesterase 1c. Molecular pharmaceutics, 21(10), 5159–5170. [DOI] [Portal]
Rijmers, J., Retmana, I. A., Bui, V., Arguedas, D., Lebre, M. C., Sparidans, R. W., Beijnen, J. H., & Schinkel, A. H. (2024). ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure. Biomedicine and Pharmacotherapy, 175, Article 116720. [DOI] [Repository]
Li, W., Sparidans, R. W., Wang, Y., Martins, M. L. F., de Waart, D. R., van Tellingen, O., Song, J.-Y., Lebre, M. C., van Hoppe, S., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2024). Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs. Biomedicine and Pharmacotherapy, 175, Article 116644. [DOI] [Repository]
Loos, N. H. C., Sparidans, R. W., Heydari, P., Bui, V., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2024). The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib. Toxicology and Applied Pharmacology, 485, Article 116911. [DOI] [Repository]
Retmana, I. A., Çelebi, N., Rijmers, J., Schinkel, A. H., Beijnen, J. H., & Sparidans, R. W. (2024). Development and validation of an LC-MS/MS method for the quantification of KRASG12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1232, 1-11. Article 123964. [DOI] [Repository]
2023
Scholarly publications
de Jong, L. A. W., Sparidans, R. W., & van den Heuvel, M. M. (2023). Cerebrospinal Fluid Concentration of the RET Inhibitor Pralsetinib: A Case Report. Case Reports in Oncology, 16(1), 1579-1585. [DOI] [Repository]
Retmana, I. A., Loos, N. H. C., Schinkel, A. H., Beijnen, J. H., & Sparidans, R. W. (2023). Development and validation of an HPLC-MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue-related matrices. Biomedical Chromatography, 37(11), Article e5720. [DOI] [Repository]
Loos, N. H. C., Retmana, I. A., Rijmers, J., Wang, Y., Gan, C., Lebre, M. C., Sparidans, R. W., Beijnen, J. H., & Schinkel, A. H. (2023). Pharmacokinetics of the KRAS
G12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c. Biomedicine and Pharmacotherapy, 166, Article 115304. [DOI]
Retmana, I. A., Loos, N. H. C., Schinkel, A. H., Beijnen, J. H., & Sparidans, R. W. (2023). Validated LC-MS/MS method for simultaneous quantification of KRASG12C inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 235, Article 115612. [DOI] [Repository]
Li, W., Iusuf, D., Sparidans, R. W., Wagenaar, E., Wang, Y., de Waart, D. R., Martins, M. L. F., van Hoppe, S., Lebre, M. C., van Tellingen, O., Beijnen, J. H., & Schinkel, A. H. (2023). Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugs. Pharmacological Research, 190, Article 106724. [DOI] [Repository]
2022
Scholarly publications
Susam, M. M., Wang, J., Schinkel, A. H., Beijnen, J. H., & Sparidans, R. W. (2022). Bioanalytical assay for the quantification of the tyrosine kinase inhibitor EAI045 and its major metabolite PIA in mouse plasma and tissue homogenates using liquid chromatography–tandem mass spectrometry. Biomedical Chromatography, 36(11), Article e5457. [DOI] [Repository]
Wang, J., Susam, M. M., Gan, C., Sparidans, R. W., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2022). P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure. Pharmaceuticals (Basel, Switzerland), 15(9), Article 1124. [DOI] [Repository]
van Bavel, J. J. A., Pham, C., Beekman, H. D. M., Houtman, M. J. C., Bossu, A., Sparidans, R. W., van der Heyden, M. A. G., & Vos, M. A. (2022). PI3K/mTOR inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the AV block dog model. Frontiers in Cardiovascular Medicine, 9, 1-14. Article 956538. [DOI] [Repository]
Li, W., Lehutova, D., Sparidans, R. W., Heydari, P., Wang, J., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2022). ABCB1 restricts brain accumulation of the novel RORγ agonist cintirorgon, while OATP1A/1B and CYP3A limit its oral availability. European Journal of Pharmaceutics and Biopharmaceutics, 177, 135-146. [DOI] [Repository]
Loos, N. H. C., Retmana, I. A., Li, W., Martins, M. L. F., Lebre, M. C., Sparidans, R. W., Beijnen, J. H., & Schinkel, A. H. (2022). ABCB1 limits brain exposure of the KRAS G12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability. Pharmacological Research, 178, 1-11. Article 106137. [DOI] [Repository]
Ahmed, S., Sparidans, R. W., Lu, J., Mihaila, S. M., Gerritsen, K. G. F., & Masereeuw, R. (2022). A robust, accurate, sensitive LC-MS/MS method to measure indoxyl sulfate, validated for plasma and kidney cells. Biomedical Chromatography, 36(5), 1-10. Article e5307. [DOI] [Repository]
Wang, Y., Sparidans, R. W., Wang, J., Li, W., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2022). Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib. European Journal of Pharmaceutics and Biopharmaceutics, 170, 197-207. [DOI] [Repository]
Heydari, P., Li, W., Schinkel, A. H., Beijnen, J. H., & Sparidans, R. W. (2022). Development and validation of an LC-MS/MS assay for the quantification of cintirorgon (LYC-55716) in mouse plasma and tissue homogenates. Journal of Pharmaceutical and Biomedical Analysis, 207, 1-7. Article 114421. [DOI] [Repository]
2021
Scholarly publications
Wang, Y., Sparidans, R. W., Potters, S., Şentürk, R., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2021). P-glycoprotein (Abcb1/mdr1) and bcrp (abcg2) limit brain accumulation and cytochrome p450-3a (cyp3a) restricts oral exposure of the ret inhibitor selpercatinib (retevmo). Pharmaceuticals, 14(11), 1-22. Article 1087. [DOI] [Repository]
Li, W., Sparidans, R. W., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2021). Abcb1 and abcg2 control brain accumulation and intestinal disposition of the novel ros1/trk/alk inhibitor repotrectinib, while oatp1a/1b, abcg2, and cyp3a limit its oral availability. Pharmaceutics, 13(11), 1-17. Article 1761. [DOI] [Repository]
Wang, Y., Sparidans, R. W., Potters, S., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2021). ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib. Pharmacological Research, 172, 1-12. Article 105850. [DOI] [Repository]
Retmana, I. A., Loos, N. H. C., Schinkel, A. H., Beijnen, J. H., & Sparidans, R. W. (2021). Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1174, 1-8. Article 122718. [DOI] [Repository]
Li, W., Sparidans, R. W., Martins, M. L. F., El-Lari, M., Lebre, M. C., van Tellingen, O., Beijnen, J. H., & Schinkel, A. H. (2021). ABCB1 and ABCG2 restrict brain and testis accumulation and, alongside CYP3A, limit oral availability of the novel TRK inhibitor selitrectinib. Molecular Cancer Therapeutics, 20(6), 1173-1182. [DOI] [Repository]
Rood, J. J. M., Toraño, J. S., Somovilla, V. J., Beijnen, J. H., & Sparidans, R. W. (2021). Bioanalysis of erlotinib, its O-demethylated metabolites OSI-413 and OSI-420, and other metabolites by liquid chromatography-tandem mass spectrometry with additional ion mobility identification. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1166, Article 122554. [DOI] [Repository]
Retmana, I. A., Beijnen, J. H., & Sparidans, R. W. (2021). Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1162, 1-17. Article 122466. [DOI] [Repository]
Rood, J. J. M., Jamalpoor, A., van Hoppe, S., van Haren, M. J., Wasmann, R. E., Janssen, M. J., Schinkel, A. H., Masereeuw, R., Beijnen, J. H., & Sparidans, R. W. (2021). Extrahepatic metabolism of ibrutinib. Investigational New Drugs, 39(1), 1-14. [DOI] [Repository]
2020
Scholarly publications
Şentürk, R., Wang, Y., Schinkel, A. H., Beijnen, J. H., & Sparidans, R. W. (2020). Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1147, Article 122131. [DOI] [Repository]
Li, W., Perpinioti, N., Schinkel, A. H., Beijnen, J. H., & Sparidans, R. W. (2020). Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1144, Article 122098. [DOI] [Repository]
Wang, Y., Sparidans, R. W., Li, W., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2020). OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. British Journal of Pharmacology, 177(13), 3060-3074. [DOI] [Portal]
Rood, J. J. M., van Haren, M. J., Beijnen, J. H., & Sparidans, R. W. (2020). Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 177, 1-9. Article 112871. [DOI] [Repository]
Li, W., Sparidans, R., El-Lari, M., Wang, Y., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2020). P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). International Journal of Pharmaceutics, 573, 1-8. Article 118842. [DOI] [Repository]
2019
Scholarly publications
Sparidans, R. W., Li, W., Schinkel, A. H., & Beijnen, J. H. (2019). Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1122-1123, 78-82. [DOI] [Repository]
van Hoppe, S., Jamalpoor, A., Rood, J. J. M., Wagenaar, E., Sparidans, R. W., Beijnen, J. H., & Schinkel, A. H. (2019). Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Pharmacological Research, 146, Article 104297. [DOI] [Repository]
Dogan-Topal, B., Li, W., Schinkel, A. H., Beijnen, J. H., & Sparidans, R. W. (2019). Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1110-1111, 116-123. [DOI] [Repository]
Li, W., Sparidans, R. W., Wang, Y., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2019). Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. European Journal of Pharmaceutics and Biopharmaceutics, 136, 120-130. [DOI] [Repository]
Wang, J., Gan, C., Retmana, I. A., Sparidans, R. W., Li, W., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2019). P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice. International Journal of Pharmaceutics, 556, 172-180. [DOI] [Repository]
2018
Scholarly publications
Van Hoppe, S., Rood, J. J. M., Buil, L., Wagenaar, E., Sparidans, R. W., Beijnen, J. H., & Schinkel, A. H. (2018). P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, while Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. Molecular Pharmaceutics, 15(11), 5124-5134. [DOI] [Repository]
Li, W., Sparidans, R. W., Wang, Y., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2018). P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability. Pharmacological Research, 137, 47-55. [DOI] [Repository]
Sparidans, R. W., Wang, Y., Schinkel, A. H., Schellens, J. H. M., & Beijnen, J. H. (2018). Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1102-1103, 167-172. [DOI] [Repository]
Li, W., Sparidans, R. W., Wang, Y., Lebre, M. C., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2018). P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. International Journal of Cancer, 143(8), 2029-2038. [DOI] [Repository]
Rood, J. J. M., Dormans, P. J. A., van Haren, M. J., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2018). Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1090, 14-21. [DOI] [Repository]
Sparidans, R. W., Li, W., Schinkel, A. H., Schellens, J. H. M., & Beijnen, J. H. (2018). Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates. Journal of Pharmaceutical and Biomedical Analysis, 161, 136-143. [DOI] [Portal]
Spatari, C., Li, W., Schinkel, A. H., Ragno, G., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2018). Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1083, 204-208. [DOI] [Repository]
Gholizadeh, S., Dolman, E. M., Wieriks, R., Sparidans, R. W., Hennink, W. E., & Kok, R. J. (2018). Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells. Pharmaceutical Research, 35(4), Article 85. [DOI] [Repository]
Jamalpoor, A., Sparidans, R. W., Casellas, C. P., Rood, J. J. M., Joshi, M., Masereeuw, R., & Janssen, M. J. (2018). Quantification of cystine in human renal proximal tubule cells using liquid chromatography-tandem mass spectrometry. Biomedical Chromatography, 32(8), 1-7. Article e4238. [DOI] [Repository]
Wang, J., Gan, C., Sparidans, R. W., Wagenaar, E., van Hoppe, S., Beijnen, J. H., & Schinkel, A. H. (2018). P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice. Pharmacological Research, 129, 414-423. [DOI] [Portal]
2017
Scholarly publications
Van Hoppe, S., Rood, G.-J., Wagenaar, E., Sparidans, R., Beijnen, J., & Schinkel, A. (2017). Breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1) transport ibrutinib and may restrict its oral availability and brain accumulation, whereas CYP3A4 limits ibrutinib oral availability. Cancer Research, 77(13), Article 5218. [DOI]
Kort, A., van Hoppe, S., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2017). Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2). Molecular Pharmaceutics, 14(10), 3258-3268. [DOI] [Repository]
Retmana, I. A., Wang, J., Schinkel, A. H., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2017). Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1061-1062, 300-305. [DOI] [Repository]
van Hoppe, S., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2017). Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacological Research, 120, 43-50. [DOI] [Repository]
Lin, F., de Gooijer, M. C., Hanekamp, D., Chandrasekaran, G., Buil, L. C. M., Thota, N., Sparidans, R. W., Beijnen, J. H., Würdinger, T., & van Tellingen, O. (2017). PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-Grade Glioma in Clinically Relevant Mouse Models. Clinical Cancer Research, 32(5), 1286-1298. [DOI] [Repository]
2016
Scholarly publications
Sparidans, R. W., Kort, A., Schinkel, A. H., Schellens, J. H. M., & Beijnen, J. H. (2016). Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1023-1024, 24-9. [DOI] [Repository]
Rood, J. J. M., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2016). Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology. Journal of Pharmaceutical and Biomedical Analysis, 130, 244-263. [DOI] [Repository]
Rood, J. J. M., van Bussel, M. T. J., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2016). Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1031, 80-85. [DOI] [Repository]
Sparidans, R. W., Rosing, H., Rood, J. J. M., Schellens, J. H. M., & Beijnen, J. H. (2016). Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1033-1034, 390-398. [DOI] [Repository]
Rood, J. J. M., van Hoppe, S., Schinkel, A. H., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2016). Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 118, 123-131. [DOI] [Repository]
Sparidans, R. W., van Hoppe, S., Rood, J. J. M., Schinkel, A. H., Schellens, J. H. M., & Beijnen, J. H. (2016). Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction. Journal of chromatography. B, 1012-1013, 118-123. [DOI] [Repository]
Professional publications
Tahmassian, R., Tan, H. L., Linnenbank, A. C., Huitema, A. D. R., Sparidans, R. W., Yu, H., Beijnen, J. H., & Langendijk, P. N. J. (2016). Relatie tussen farmacokinetiek van ajmaline en ST-elevatie bij de diagnostiek van het Brugada-syndroom. Nederlands Platform voor Farmaceutisch Onderzoek, 2016(1), 1-5. Article a1603. https://www.knmp.nl/resolveuid/ba01d0dc695f4fa998c1b919295c47bd [Repository]
2015
Scholarly publications
Kort, A., Sparidans, R., Wagenaar, E., Beijnen, J., & Schinkel, A. H. (2015). Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Pharmacological Research, 102, 200-207. [DOI] [Repository]
Kort, A., Durmus, S., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2015). Brain and testis accumulation of regorafenib is restricted by breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). Pharmaceutical Research, 32(7), 2205-2216. [DOI] [Repository]
Dolman, M. E. M., Poon, E., Ebus, M. E., Den Hartog, I. J. M., Van Noesel, C. J. M., Jamin, Y., Hallsworth, A., Robinson, S. P., Petrie, K., Sparidans, R. W., Kok, R. J., Versteeg, R., Caron, H. N., Chesler, L., & Molenaar, J. J. (2015). Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clinical Cancer Research, 21(22), 5100-5109. [DOI] [Portal]
Hahn, C. S., Scott, D. W., Xu, X., Roda, M. A., Payne, G. A., Wells, J. M., Viera, L., Winstead, C. J., Bratcher, P., Sparidans, R. W., Redegeld, F. A., Jackson, P. L., Folkerts, G., Blalock, J. E., Patel, R. P., & Gaggar, A. (2015). The matrikine N-α-PGP couples extracellular matrix fragmentation to endothelial permeability. Science advances, 1(3). [DOI] [Repository]
Vogel, C. J., Smit, M. A., Maddalo, G., Possik, P. A., Sparidans, R. W., van der Burg, S. H., Verdegaal, E. M., Heck, A. J. R., Samatar, A. A., Beijnen, J. H., Altelaar, A. F. M., & Peeper, D. S. (2015). Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK. Pigment Cell and Melanoma Research, 28(3), 307-317. [DOI] [Repository]
Durmus, S., Sparidans, R. W., van Esch, A., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2015). Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699). Pharmaceutical Research, 32(1), 37-46. [DOI] [Repository]
Dolman, M. E. M., Westerhout, E. M., Hamdi, M., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2015). Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate. Journal of Pharmaceutical and Biomedical Analysis, 107, 403-408. [DOI] [Repository]
2014
Scholarly publications
Dolman, M. E. M., den Hartog, I. J. M., Molenaar, J. J., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2014). Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis, 92, 144-148. [DOI]
Luethi, D., Durmus, S., Schinkel, A. H., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2014). Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma. Biomedical Chromatography, 28(10), 1366-1370. [DOI]
Dolman, M. E. M., den Hartog, I. J. M., Molenaar, J. J., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2014). Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis, 88, 216-220. [DOI]
Koelink, P. J., Overbeek, S. A., Braber, S., Morgan, M. E., Henricks, P. A. J., Abdul Roda, M., Verspaget, H. W., Wolfkamp, S. C., te Velde, A. A., Jones, C. W., Jackson, P. L., Blalock, J. E., Sparidans, R. W., Kruijtzer, J. A. W., Garssen, J., Folkerts, G., & Kraneveld, A. D. (2014). Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease. Gut, 63, 578-587. [DOI]
Tang, S. C., Sparidans, R. W., Cheung, K. L., Fukami, T., Durmus, S., Wagenaar, E., Yokoi, T., van Vlijmen, B. J. M., Beijnen, J. H., & Schinkel, A. H. (2014). P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice. Clinical Cancer Research, 20(12), 3133-3145. [DOI]
Chuan Tang, S., Nguyen, L. N., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2014). Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. International Journal of Cancer, 134(6), 1484-94.
Sparidans, R. W., Durmus, S., Schinkel, A. H., Schellens, J. H. M., & Beijnen, J. H. (2014). Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. Journal of Pharmaceutical and Biomedical Analysis, 88, 626-629. [DOI]
2013
Scholarly publications
Durmus, S., Xu, N., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2013). P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict the brain penetration of the Janus family of tyrosine kinase (JAK) inhibitor CYT387. FASEB Journal, 27(1).
Tang, S. C., De Vries, N., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2013). Impact of P-Glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinibs. Journal of Pharmacology and Experimental Therapeutics, 346(3), 486-494. [DOI]
Luethi, D., Durmus, S., Schinkel, A. H., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2013). Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma. Journal of chromatography. B, 934, 22-25. [DOI]
Sparidans, R. W., Durmus, S., Schinkel, A. H., Schellens, J. H. M., & Beijnen, J. H. (2013). Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma. Journal of chromatography. B, 925, 124-8. [DOI]
Tang, S. C., de Vries, N., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2013). Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib. Journal of Pharmacology and Experimental Therapeutics, 346(3), 486-94.
Durmus, S., Xu, N., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2013). P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387. Pharmacological Research, 76, 9-16.
2012
Scholarly publications
Dolman, M., Harmsen, S., Pieters, E. H. E., Sparidans, R. W., Lacombe, M., Szokol, B., Orfi, L., Kéri, G., Storm, G., Hennink, W. E., & Kok, R. J. (2012). Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells. International Journal of Nanomedicine, 7, 417-433. [DOI]
Durmus, S., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2012). Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the p-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Molecular Pharmaceutics, 9(11), 3236-3245. [DOI]
Sparidans, R. W., Tang, S. C., Nguyen, L. N., Schinkel, A. H., Schellens, J. H. M., & Beijnen, J. H. (2012). Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma. Journal of chromatography. B, 905, 150-154. [DOI]
Sparidans, R. W., Durmus, S., Schinkel, A. H., Schellens, J. H. M., & Beijnen, J. H. (2012). Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma. Journal of chromatography. B, 889-890, 144-147. [DOI]
Sparidans, R. W., Durmus, S., Xu, N., Schinkel, A. H., Schellens, J. H. M., & Beijnen, J. H. (2012). Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma. Journal of chromatography. B, 895-896, 174-177. [DOI]
Sparidans, R. W., Durmus, S., Xu, N., Schinkel, A. H., Schellens, J. H. M., & Beijnen, J. H. (2012). Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma. Journal of chromatography. B, 895-896, 169-173. [DOI]
Dolman, E., van Dorenmalen, K. M. A., Pieters, E. H. E., Sparidans, R. W., Lacombe, M., Szokol, B., Orfi, L., Kéri, G., Bovenschen, N., Storm, G., Hennink, W. E., & Kok, R. J. (2012). Dendrimer-based macromolecular conjugate for the kidney-directed delivery of a multitargeted sunitinib analogue. Macromolecular Bioscience, 12(1), 93-103. [DOI]
Iusuf, D., Sparidans, R. W., van Esch, A., Hobbs, M., Kenworthy, K. E., van de Steeg, E., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2012). Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice. Molecular Pharmaceutics, 9(9), 2497-504.
van Velsen, S. G. A., de Roos, M. P., Haeck, I. M., Sparidans, R. W., & Bruijnzeel - Koomen, C. A. F. M. (2012). The potency of clobetasol propionate: Serum levels of clobetasol propionate and adrenal function during therapy with 0.05% clobetasol propionate in patients with severe atopic dermatitis. The journal of dermatological treatment, 23(1), 16-20. http://www.ncbi.nlm.nih.gov/pubmed/21254880
Deenen, MJ., Klumpen, H. J., Richel, D. J., Sparidans, R. W., Weterman, M. J., Beijnen, J. H., Schellens, J. H. M., & Wilmink, J. T. (2012). Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. Investigational New Drugs, 30(4), 1557-65.
Dolman, M. E. M., van Dorenmalen, K. M. A., Pieters, E. H. E., Sparidans, R. W., Lacombe, M., Szokol, B., Örfi, L., Kéri, G., Bovenschen, N., Storm, G., Hennink, W. E., & Kok, R. J. (2012). Dendrimer-Based Macromolecular Conjugate for the Kidney-Directed Delivery of a Multitargeted Sunitinib Analoguw. Macromolecular Bioscience, 12(1), 93-103. http://www.ncbi.nlm.nih.gov/pubmed/21998092
Sparidans, R. W., Ahmed, T. T. A., Muilwijk, E. W., Welzen, M. E. B., Schellens, J. H. M., & Beijnen, J. H. (2012). Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma. Journal of chromatography. B, 137-140. [DOI]
Goey, A. K. L., Rosing, H., Meijerman, I., Sparidans, R. W., Schellens, J. H. M., & Beijnen, J. H. (2012). The bioanalysis of the major Echinacea purpurea constituents dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides in human plasma using LC-MS/MS. Journal of chromatography. B, 902, 151-156.
2011
Scholarly publications
Langendijk, P. N. J., Feberwee, T., Andrews, L., Van Kan, E., Sparidans, R., Tan, H., & Beijnen, J. (2011). Pharmacokinetics of ajmaline in diagnosis of Brugada syndrome: New data for an old drug. Therapeutic Drug Monitoring, 33(4), 558. [DOI]
Poller, B., Iusuf, D., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2011). Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug Metabolism and Disposition, 39(5), 729-735. [DOI]
Goey, A., Sparidans, R. W., Meijerman, I., Rosing, H., Schellens, J. H. M., & Beijnen, J. H. (2011). A sensitive LC-MS/MS method for the quantitative analysis of the Echinacea purpurea constituent undeca-2-ene-8,10-diynoic acid isobutylamide in human plasma. Journal of chromatography. B, 879(1), 41-48. [DOI]
Sparidans, R. W., Martens, I., Valkenburg-van Iersel, L. B. J., den Hartigh, J., Schellens, J. H. M., & Beijnen, J. H. (2011). Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma. Journal of chromatography. B, 879(21), 1851-6. [DOI]
2010
Scholarly publications
Wilmink, J., Deenen, M. J., Klümpen, H., Sparidans, R., Beijnen, J., Schellens, J. H., & Richel, D. (2010). Phase I and pharmacokinetic study of everolimus and capecitabine in patients with solid tumors. Journal of Clinical Oncology, 28(15).
Van Den Broek, I., Sparidans, R. W., Engwegen, J. Y. M. N., Cats, A., Depla, A. C. T. M., Schellens, J. H. M., & Beijnen, J. H. (2010). Evaluation of human neutrophil peptide-1, -2 and -3 as serum markers for colorectal cancer. Cancer Biomarkers, 7(2), 109-115. [DOI]
Sparidans, R. W., van Velsen, S. G. A., de Roos, M. P., Schellens, J. H. M., Bruijnzeel-Koomen, C. A. F. M., & Beijnen, J. H. (2010). Liquid chromatography-tandem mass spectrometric assay for clobetasol propionate in human serum from patients with atopic dermatitis. Journal of chromatography. B, 878(23), 2150-2154. [DOI]
Sparidans, R. W., Iusuf, D., Schinkel, A. H., Schellens, J. H. M., & Beijnen, J. H. (2010). Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates. Journal of chromatography. B, 878(28), 2751-9. [DOI]
van Winden, A. W. J., van den Broek, I., Gast, G. C. M., Engwegen, J. Y., Sparidans, R. W., van Dulken, E. J., Depla, A. C., Cats, A., Schellens, J. H., Peeters, P. H. M., Beijnen, J. H., & van Gils, C. H. (2010). Serum degradome markers for the detection of breast cancer. Journal of Proteome Research, 9(8), 3781-3788.
Lagas, J. S., van Waterschoot, R. A., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2010). Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Molecular Cancer Therapeutics, 9(2), 319-326.
van den Broek, I., Sparidans, R. W., Schellens, J. H. M., & Beijnen, J. H. (2010). Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry. Journal of chromatography. B, 878(5-6), 590-602.
Lagas, J. S., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2010). Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Molecular Pharmacology, 77(4), 687-694.
van den Broek, I., Sparidans, R. W., Schellens, J. H. M., & Beijnen, J. H. (2010). Validation of a quantitative assay for human neutrophil peptide-1, -2, and -3 in human plasma and serum by liquid chromatography coupled to tandem mass spectrometry. Journal of chromatography. B, 878(15-16), 1085-1092.
Sparidans, R. W., Langendijk, P., Boers, E., van Kan, E. J. M., Tan, H. L., & Beijnen, J. H. (2010). Liquid chromatographic assay with fluorescence detection to determine ajmaline in serum from patients with suspected Brugada syndrome. Journal of chromatography. B, 878(23), 2168-2172.
van den Broek, I., Sparidans, R. W., Schellens, J. H. M., & Beijnen, J. H. (2010). Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers. Clinical Proteomics, 6, 115-127. [DOI] [Repository]
van den Broek, I., Sparidans, R. W., van Winden, A. W. J., Gast, M. C., van Dulken, E. J., Schellens, J. H. M., & Beijnen, J. H. (2010). The absolute quantification of eight inter-α-trypsin inhibitor heavy chain 4 (ITIH4)-derived peptides in serum from breast cancer patients. Proteomics - Clinical Applications, 4(12), 931-939. [DOI]
van den Broek, I., Sparidans, R. W., Schellens, J. H. M., & Beijnen, J. H. (2010). Sensitive liquid chromatography/tandem mass spectrometry assay for absolute quantification of ITIH4-derived putative biomarker peptides in clinical serum samples. Rapid Communications in Mass Spectrometry, 24(13), 1842-1850.
2009
Scholarly publications
Sparidans, R. W., Vlaming, M. L. H., Lagas, J. S., Schinkel, A. H., Schellens, J. H. M., & Beijnen, J. H. (2009). Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. Journal of chromatography. B, 877(3), 269-76. [DOI]
Sparidans, R. W., Iusuf, D., Schinkel, A. H., Schellens, J. H. M., & Beijnen, J. H. (2009). Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. Journal of chromatography. B, 877(32), 4090-4096. [DOI]
van Waterschoot, R. A., Rooswinkel, R. W., Sparidans, R. W., van Herwaarden, A. E., Beijnen, J. H., & Schinkel, A. H. (2009). Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam. Drug Metabolism and Disposition, 37(12), 2305-2313.
2008
Scholarly publications
Van Waterschoot, R. A. B., Van Herwaarden, A. E., Lagas, J. S., Sparidans, R. W., Wagenaar, E., Van Der Kruijssen, C. M. M., Goldstein, J. A., Zeldin, D. C., Beijnen, J. H., & Schinkel, A. H. (2008). Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Molecular Pharmacology, 73(3), 1029-1036. [DOI]
Attema-de Jonge, M. E., Bekkers, J. M., Oudemans-van Straaten, H. M., Sparidans, R. W., & Franssen, E. J. F. (2008). Simple and sensitive method for quantification of low tobramycin concentrations in human plasma using HPLC-MS/MS. Journal of chromatography. B, 862(1-2), 257-262. [DOI]
Lagas, J. S., Sparidans, R. W., Van Waterschoot, R. A. B., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2008). P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin. Antimicrobial Agents and Chemotherapy, 52(3), 1034-1039. [DOI]
Sparidans, R. W., Lagas, J. S., Schinkel, A. H., Schellens, J. H. M., & Beijnen, J. H. (2008). Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma. Journal of chromatography. B, 872(1-2), 77-82. [DOI]
van den Broek, I., Sparidans, R. W., Schellens, J. H. M., & Beijnen, J. H. (2008). Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH4 with biomarker potential in human plasma and serum. Rapid Communications in Mass Spectrometry, 22(18), 2915-2928.
van den Broek, I., Sparidans, R. W., Schellens, J. H. M., & Beijnen, J. H. (2008). Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. Journal of chromatography. B, 872(1-2), 1-22.
2007
Scholarly publications
van Iersel, L. B. J., Verlaan, M. R., Vahrmeijer, A. L., van Persijn van Meerten, E. L., Tijl, F. G. J., Sparidans, R. W., Gelderblom, H., Kuppen, P. J. K., Tollenaar, R. A. E. M., & van de Velde, C. J. H. (2007). Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: A clinical and pharmacologic evaluation. European Journal of Surgical Oncology, 33(7), 874-881. [DOI]
van den Broek, I., Sparidans, R. W., Schellens, J. H. M., & Beijnen, J. H. (2007). Enzymatic digestion as a tool for the LC-MS/MS quantification of large peptides in biological matrices: Measurement of chymotryptic fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma. Journal of chromatography. B, 854(1-2), 245-259. [DOI]
Sparidans, R. W., Prins, J. M., Schellens, J. H. M., & Beijnen, J. H. (2007). Liquid chromatography-tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma. Biomedical Chromatography, 21(6), 621-7. [DOI]
Sparidans, R. W., Lagas, J. S., Schinkel, A. H., Schellens, J. H. M., & Beijnen, J. H. (2007). Liquid chromatography-tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium. Journal of chromatography. B, 855(2), 200-10. [DOI]
Brandon, E. F. A., Sparidans, R. W., van Ooijen, R. D., Meijerman, I., Lazaro, L. L., Manzanares, I., Beijnen, J. H., & Schellens, J. H. M. (2007). In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Investigational New Drugs, 25, 9-19.
2006
Scholarly publications
Van Der Elst, A., Oosterling, S. J., Paul, M. A., Vonk, A. M. A., Sparidans, R. W., & Van Der Sijp, J. R. M. (2006). Isolated lung perfusion with melphalan: Pharmacokinetics and toxicity in a pig model. Journal of Surgical Oncology, 93(5), 410-416. [DOI]
van den Broek, I., Sparidans, R. W., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2006). Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, 837(1-2), 49-58. [DOI]
Sparidans, R. W., Bosch, T. M., Jörger, M., Schellens, J. H. M., & Beijnen, J. H. (2006). Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. Journal of chromatography. B, 839(1-2), 45-53. [DOI]
Sparidans, R. W., Dost, F., Crommentuyn, K. M. L., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2006). Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma. Biomedical Chromatography, 20(8), 671-3. [DOI]
Brandon, E. F. A., Sparidans, R. W., Guijt, KJ., Lowenthal, S., Meijerman, I., Beijnen, J. H., & Schellens, J. H. M. (2006). In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Investigational New Drugs, 24(1), 3-14.
Sparidans, R. W., Dost, F., Crommentuyn, K. M. L., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2006). Liquid chromatographic assay for the protease inhibitor atazanavir in plasma. Biomedical Chromatography, 20(1), 72-6.
2005
Scholarly publications
Rademaker-Lakhai, J. M., Crul, M., Pluim, D., Sparidans, R. W., Baas, P., Beijnen, J. H., Van Zandwijk, N., & Schellens, J. H. M. (2005). Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Anti-Cancer Drugs, 16(9), 1029-1036. [DOI]
Brandon, E. F. A., Meijerman, I., Klijn, J. S., Den Arend, D., Sparidans, R. W., Lazaro, L. L., Beijnen, J. H., & Schellens, J. H. M. (2005). In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: Influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. Anti-Cancer Drugs, 16(9), 935-943. [DOI]
Siegel-Lakhai, W. S., Crul, M., Zhang, S., Sparidans, R. W., Pluim, D., Howes, A., Solanki, B., Beijnen, J. H., & Schellens, J. H. M. (2005). Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. British Journal of Cancer, 93(11), 1222-1229. [DOI]
Zandvliet, A. S., Huitema, A. D. R., de Jonge, M. E., den Hoed, R., Sparidans, R. W., Hendriks, V. M., van den Brink, W., van Ree, J. M., & Beijnen, J. H. (2005). Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. Basic & Clinical Pharmacology & Toxicology, 96(1), 71-79.
van Herwaarden, A. E., Smit, J. W., Sparidans, R. W., Wagenaar, E., Van der Kruijssen, C. M. M., Schellens, J. H. M., Beijnen, J. H., & Schinkel, A. H. (2005). Midazolam and cyclosporin A metabolism in transgenic mice with liver-specific expression of human CYP3A4. Drug Metabolism and Disposition, 33(7), 892-895.
Brandon, E. F. A., van Ooijen, R. D., Sparidans, R. W., Lazaro, L. L., Heck, A. J. R., Beijnen, J. H., & Schellens, J. H. M. (2005). Structure elucidation of aplidine metabolites formed in vitro by human liver microsomes using triple quadrupole mass spectrometry. Journal of Mass Spectrometry, 40(6), 821-831.
2004
Scholarly publications
Brandon, E. F. A., Sparidans, R., Meijerman, I., Manzanares, I., Beijnen, J. H., & Schellens, J. H. M. (2004). In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug. Investigational New Drugs, 22(3), 241-251. [DOI]
Crommentuyn, K. M. L., Mulder, J. W., Sparidans, R. W., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2004). Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. Clinical Infectious Diseases, 38(8), e73-5.
Sparidans, R. W., Schellens, J. H. M., López-Lázaro, L., Jimeno, J. M., & Beijnen, J. H. (2004). Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4'-hydrazino-2-stilbazole. Biomedical Chromatography, 18(1), 16-20. [DOI]
van Ruth, S., Mathôt, R. A. A., Sparidans, R. W., Beijnen, J. H., Verwaal, V. J., & Zoetmulder, F. A. N. (2004). Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. Clinical Pharmacokinetics, 43, 131-143.
Sankatsing, S. U., Hoggard, P. G., Huitema, A. D. R., Sparidans, R. W., Kewn, S., Crommentuyn, K. M. L., Lange, J. M., Beijnen, J. H., Back, D. J., & Prins, J. M. (2004). Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Clinical Pharmacokinetics, 43, 823-832.
van den Bongard, HJ., Sparidans, R. W., Critchley, DJ., Beijnen, J. H., & Schellens, J. H. M. (2004). Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. Investigational New Drugs, 22(2), 151-8.
2003
Scholarly publications
Koks, C. H. W., Huitema, A. D. R., Kroon, E. D. M. B., Chuenyam, T., Sparidans, R. W., Lange, J. M. A., & Beijnen, J. H. (2003). Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons. Therapeutic Drug Monitoring, 25(2), 229-233. [DOI]
Rothbarth, J., Woutersen, R. A., Sparidans, R. W., van de Velde, C. J. H., & Mulder, G. J. (2003). Melphalan antitumor efficacy and hepatotoxicity: the effect of variable infusion duration in the hepatic artery. Journal of Pharmacology and Experimental Therapeutics, 305, 1098-1103.
Sparidans, R. W., Silvertand, L. H. H., Dost, F., Rothbarth, J., Mulder, G. J., Schellens, J. H. M., & Beijnen, J. H. (2003). Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue. Biomedical Chromatography, 17, 458-464.
Sparidans, R. W., Crommentuyn, K. M. L., Schellens, J. H. M., & Beijnen, J. H. (2003). Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde. Journal of chromatography. B, 791, 227-233.
Crul, M., Schoemaker, N. E., Pluim, D., Maliepaard, M., Underberg, R. W., Schot, M., Sparidans, R. W., Baas, P., Beijnen, J. H., van Zandwijk, N., & Schellens, J. H. M. (2003). Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clinical Cancer Research, 9, 3526-3533.
2002
Scholarly publications
Koks, C. H. W., Sparidans, R. W., Lucassen, G., Crommentuyn, K. M. L., & Beijnen, J. H. (2002). Selective high-performance liquid chromatographic assay for itraconazole and hydroxyitraconazole in plasma from human immunodeficiency virus-infected patients. Journal of chromatography. B, 767(1), 103-110. [DOI]
Sparidans, R. W., Crul, M., Schellens, J. H. M., & Beijnen, J. H. (2002). Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine-triphosphate in human white blood cells. Journal of chromatography. B, 780, 423-430.
Koks, C. H. W., Sparidans, R. W., Lucassen, G., Krommentuyn, K. M. L., & Beijnen, J. H. (2002). Selective high-performance liquid chromatographic assay for itraconazole and hydroxyitroconazole in human immunodeficiency virus-infected plasma. Journal of chromatography. B, 767, 103-110.
Cremers, S., Sparidans, R. W., den Hartigh, J., Hamdy, N., Vermeij, P., & Papapoulos, S. (2002). A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. European Journal of Clinical Pharmacology, 57, 883-890.
Rothbarth, J., Sparidans, R. W., Beijnen, J. H., Schultze Kool, L. J., Putter, H., van de Velde, C. J. H., & Mulder, G. J. (2002). Reduce liver uptake of arterially infused melphalan during retrograde rat liver infusion with unaffected liver tumor uptake. Journal of Pharmacology and Experimental Therapeutics, 303(2), 736-740. [DOI]
Other output
Crul, M., Schoemaker, N., Baas, P., Pluim, D., Sparidans, R. W., Beijnen, J. H., van Zandwijk, N., & Schellens, J. H. M. (2002). Randomized phase I and pharmacological study of 2-weekly gemcitabine and cisplatin in advanced non-small cell lung cancer. British Journal of Clinical Pharmacology, 54, 554-555.
2001
Scholarly publications
Sparidans, R. W., Rosing, H., Hillebrand, M. J. X., López-Lázaro, L., Jimeno, J. M., Manzanares, I., Van Kesteren, C., Cvitkovic, E., Van Oosterom, A. T., Schellens, J. H. M., & Beijnen, J. H. (2001). Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man. Anti-Cancer Drugs, 12(8), 653-666. [DOI]
Sparidans, R. W., Hoetelmans, R. M., & Beijnen, J. H. (2001). Liquid chromatographic assay for simultaneous determination of abacavir and mycophenolic acid in human plasma using dual spectrophotometric detection. Journal of chromatography. B, Biomedical sciences and applications, 750(1), 155-61.
Sparidans, R. W., Stokvis, E., Jimeno, J. M., López-Lázaro, L., Schellens, J. H., & Beijnen, J. H. (2001). Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F. Anti-Cancer Drugs, 12(7), 575-582.
Waterval, J. C. M., Bloks, J. C., Sparidans, R. W., Beijnen, J. H., Rodriguez-Campos, I. M., Bult, A., Lingeman, H., & Underberg, W. J. M. (2001). Degradation kinetics of aplidine, a new marine antitumoural cyclic peptide, in aqueous solution. Journal of chromatography. B, Biomedical sciences and applications, 754, 161-168.
Sparidans, R. W., Hoetelmans, R. M. W., & Beijnen, J. H. (2001). Liquid chromatographic assay for simultaneous analysis of abacavir and mycophenolic acid in human plasma using dual spectrophotometric detection. Journal of chromatography. B, Biomedical sciences and applications, 750, 155-161.
2000
Scholarly publications
Sparidans, R. W., Den Hartigh, J., Cremers, S., & Vermeij, P. (2000). Chromatographic analysis of bisphosphonates. Journal of Chromatography A, 868(1), 141-142. [DOI]
Sparidans, R. W., Den Hartigh, J., Cremers, S., Beijnen, J. H., & Vermeij, P. (2000). Semi-automatic liquid chromatographic analysis of olpadronate in urine and serum using derivatization with (9-fluorenylmethyl)chloroformate. Journal of chromatography. B, Biomedical sciences and applications, 738(2), 331-341. [DOI]
Sparidans, R. W., Hoetelmans, R. M., & Beijnen, J. H. (2000). Sensitive liquid chromatographic assay for amprenavir, a human immunodeficiency virus protease inhibitor, in human plasma, cerebrospinal fluid and semen. Journal of chromatography. B, Biomedical sciences and applications, 742(1), 185-92.
Sparidans, R. W., Hoetelmans, R. M. W., & Beijnen, J. H. (2000). Sensitive liquid chromatographic assay for amprenavir, a protease inhibitor, in human plasma, cerebrospinal fluid and semen. Journal of chromatography. B, Biomedical sciences and applications, 742, 185-192.
Sparidans, R. W., den Hartigh, J., Cremers, S., Beijnen, J. H., & Vermeij, P. (2000). Semi-automated liquid chromatographic analysis of olpadronate in urine and serum using derivatization with (9-fluorenylmethyl)chlorofromate. Journal of chromatography. B, Biomedical sciences and applications, 738, 331-341.
Evers, R., de Haas, M., Sparidans, R. W., Beijnen, J. H., Wielinga, P. R., Lankelma, J., & Borst, P. (2000). Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. British Journal of Cancer, 83, 375-383.
1999
Scholarly publications
Sparidans, R. W., & Den Hartigh, J. (1999). Chromatographic analysis of bisphosphonates. Pharmacy World and Science, 21(1), 1-10. [DOI]
Veldkamp, A. I., Sparidans, R. W., Hoetelmans, R. M. W., & Beijnen, J. H. (1999). Quantitative determination of abacavir (1592U89), a novel nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. Journal of chromatography. B, Biomedical sciences and applications, 736(1-2), 123-128. [DOI]
Sparidans, R. W., Henrar, R. E., Jimeno, J. M., Faircloth, G., Floriano, P., & Beijnen, J. H. (1999). Bioanalysis of thiocoraline, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography and fluorescence detection. Journal of chromatography. B, Biomedical sciences and applications, 726(1-2), 255-60. [DOI]
Sparidans, R. W., Kettenes-van den Bosch, J. J., van Tellingen, O., Nuyen, B., Henrar, R. E., Jimeno, J. M., Faircloth, G., Floriano, P., Rinehart, K. L., & Beijnen, J. H. (1999). Bioanalysis of aplidine, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4-hydrazino-2-stilbazole. Journal of chromatography. B, Biomedical sciences and applications, 729(1-2), 43-53. [DOI]
Sparidans, R. W., den Hartigh, J., Cremers, S., Beijnen, J. H., & Vermeij, P. (1999). Semi-automatic liquid chromatographic analysis of pamidronate in urine after derivatization with 1-naphthylisothiocyanate. Journal of chromatography. B, Biomedical sciences and applications, 730(1), 95-9. [DOI]
Sparidans, R. W., Taal, B. G., & Beijnen, J. H. (1999). Bioanalysis of m-iodobenzylguanidine in plasma by high-performance liquid chromatography after derivatization with benzoin. Journal of chromatography. B, Biomedical sciences and applications, 730(2), 193-199. [DOI]
Sparidans, R. W., Taal, B. G., & Beijnen, J. H. (1999). Bioanalysis of meta-lodovenzylguanidine in plasma by high-performance liquid chromatography after derivatization with benzoin. Journal of chromatography. B, Biomedical sciences and applications, 730, 193-199.
Sparidans, R. W., Henrar, R. E. C., Jimeno, J. M., Faircloth, G., Floriano, P., & Beijnen, J. H. (1999). Bioanalysis of thiocoraline, a new marine antitumoral depsipeptide, is plasma by high-performance liquid chromatography with fluorescence detection. Journal of chromatography. B, Biomedical sciences and applications, 726, 255-260.
Professional publications
Veldkamp, A. I., Sparidans, R. W., Hoetelmans, R. M. W., & Beijnen, J. H. (1999). Quantitative determination of abacavir (1592U89), a novel nucleoside reverse transcriptase inhibito, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. Journal of chromatography. B, Biomedical sciences and applications, 736, 123-128.
Sparidans, R. W., Veldkamp, A. I., Hoetelmans, R. M. W., & Beijnen, J. H. (1999). Improved and simplified liquid chromatographic assay for adefovir, a novel antiviral drug, in human plasma using derivatization with chloroacetaldehyde. Journal of chromatography. B, Biomedical sciences and applications, 736, 115-121.
Sparidans, R. W., den Hartigh, J., Cremers, S., Beijnen, J. H., & Vermeij, P. (1999). Semi-automated liquid chromatographic analysis of pamidronate in urine after derivatization with 1-naphthylisothiocyanate. Journal of chromatography. B, Biomedical sciences and applications, 730(1), 95-99.
1998
Scholarly publications
Sparidans, R., Twiss, I. M., & Talbot, S. (1998). Bisphosphonates in bone diseases. Pharmacy World & Science, 20(5), 206-213. [DOI]
Sparidans, R. W., Den Hartigh, J., Beijnen, J. H., & Vermeij, P. (1998). Semi-automatic liquid chromatographic analysis of pamidronate in serum and citrate plasma after derivatization with 1-naphthylisothiocyanate. Journal of chromatography. B, Biomedical applications, 705(2), 331-339. [DOI]
1997
Scholarly publications
Sparidans, R. W., Den Hartigh, J., Ramp-Koopmanschap, W. M., Langebroek, R. H., & Vermeij, P. (1997). The determination of pamidronate in pharmaceutical preparations by ion-pair liquid chromatography after derivatization with phenylisothiocyanate. Journal of Pharmaceutical and Biomedical Analysis, 16(3), 491-497. [DOI]
Sparidans, R. W., Den Hartigh, J., Beijnen, J. H., & Vermeij, P. (1997). Derivatization of pamidronate and other amino(bis)phosphonates with different isothiocyanates prior to ion-pair liquid chromatography. Journal of Chromatography A, 782(2), 211-217. [DOI]
Sparidans, R. W., Den Hartigh, J., Beijnen, J. H., & Vermeij, P. (1997). Determination of pamidronate in urine by ion-pair liquid chromatography after derivatization with 1-naphthylisothiocyanate. Journal of chromatography. B, Biomedical applications, 696(1), 137-144. [DOI]
Sparidans, R. W., den Hartogh, J., Beijnen, J. H., & Vermeij, P. (1997). Determination of pamidronate in urine by ion-pair liquid chromatography after derivatization with t-naphthylisothiocyanate. Journal of chromatography. B, Biomedical sciences and applications, 696, 137-144.
1995
Scholarly publications
Sparidans, R. W., den Hartigh, J., & Vermeij, P. (1995). High-performance ion-exchange chromatography with in-line complexation of bisphosphonates and their quality control in pharmaceutical preparations. Journal of Pharmaceutical and Biomedical Analysis, 13(12), 1545-1550. [DOI]
1994
Scholarly publications
Twiss, I. M., De Water, R., Den Hartigh, J., Sparidans, R., Ramp-Koopmanschap, W., Brill, H., Wijdeveld, M., & Vermeij, P. (1994). Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. Journal of Pharmaceutical Sciences, 83(5), 699-703. [DOI]
1990
Scholarly publications
Sparidans, R. W., Claessens, H. A., Van Doremaele, G. H. J., & Van Herk, A. M. (1990). Analysis of poly(styrene-co-methyl acrylate) and poly(styrene-co-butyl acrylate) by high-performance liquid chromatography. Journal of Chromatography A, 508(C), 319-331. [DOI]
1988
Scholarly publications
Claessens, H. A., Lemmens, A. A. G., Sparidans, R. W., & Everaerts, F. M. (1988). Pretreatment of body fluids by preparative isotachophoresis prior to chromatographic analysis. Chromatographia, 26(1), 351-358. [DOI]